New hope for Tough-to-Treat blood cancer
NCT ID NCT05563844
Summary
This study is testing a new drug called purinostat mesylate for people with a type of aggressive blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or hasn't responded to previous treatments. The main goal is to find a safe and effective dose and see how well the drug shrinks tumors. It is for adults who have already tried several other treatments without success.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ruijin Hospital of Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610000, China
Conditions
Explore the condition pages connected to this study.